Sangamo Payables Turnover vs Price To Sales Ratio Analysis

SGMO Stock

USD 2.35 0.47 16.67%

Sangamo Therapeutics financial indicator trend analysis is much more than just breaking down Sangamo Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sangamo Therapeutics is a good investment. Please check the relationship between Sangamo Therapeutics Payables Turnover and its Price To Sales Ratio accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.

Payables Turnover vs Price To Sales Ratio

Payables Turnover vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sangamo Therapeutics Payables Turnover account and Price To Sales Ratio. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Sangamo Therapeutics' Payables Turnover and Price To Sales Ratio is 0.12. Overlapping area represents the amount of variation of Payables Turnover that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Sangamo Therapeutics, assuming nothing else is changed. The correlation between historical values of Sangamo Therapeutics' Payables Turnover and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Payables Turnover of Sangamo Therapeutics are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Payables Turnover i.e., Sangamo Therapeutics' Payables Turnover and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

0.12

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Sangamo Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Sangamo Therapeutics sales, a figure that is much harder to manipulate than other Sangamo Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from Sangamo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sangamo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.As of the 19th of December 2024, Selling General Administrative is likely to grow to about 64.2 M, though Tax Provision is likely to grow to (4.3 M).

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	17.6M	20.6M	24.6M	14.1M
Net Interest Income	5.3M	9.4M	13.3M	7.9M

Reconciled Depreciation Net Interest Income

Sangamo Therapeutics fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Net Debt	Other Current Assets	Property Plant Equipment
Total Assets		0.97	-0.4	0.89	0.53	0.63	0.97	0.8	0.79	0.95	0.91	0.42	0.89	0.94	0.32	0.96	0.41	0.06	0.89	0.97	0.75	0.97	0.03	-0.78	0.7	0.51
Total Stockholder Equity	0.97		-0.31	0.81	0.46	0.56	0.89	0.73	0.7	0.86	0.84	0.32	0.83	0.88	0.21	0.96	0.54	-0.06	0.91	0.9	0.65	0.97	-0.1	-0.74	0.56	0.42
Retained Earnings	-0.4	-0.31		-0.41	-0.98	-0.96	-0.48	-0.79	-0.38	-0.56	-0.6	-0.87	-0.46	-0.51	-0.96	-0.22	0.0	-0.13	-0.11	-0.45	-0.84	-0.32	-0.22	0.19	-0.7	-0.86
Other Assets	0.89	0.81	-0.41		0.49	0.58	0.92	0.8	0.64	0.93	0.94	0.52	0.83	0.95	0.33	0.79	0.31	0.23	0.69	0.9	0.8	0.79	0.19	-0.72	0.86	0.46
Common Stock Shares Outstanding	0.53	0.46	-0.98	0.49		0.99	0.58	0.84	0.47	0.65	0.67	0.86	0.56	0.61	0.93	0.37	0.08	0.06	0.26	0.56	0.88	0.46	0.14	-0.29	0.73	0.86
Other Stockholder Equity	0.63	0.56	-0.96	0.58	0.99		0.66	0.89	0.52	0.73	0.76	0.85	0.64	0.69	0.9	0.46	0.15	0.09	0.35	0.64	0.92	0.55	0.16	-0.37	0.77	0.87
Total Liab	0.97	0.89	-0.48	0.92	0.58	0.66		0.84	0.83	0.99	0.93	0.51	0.89	0.95	0.42	0.92	0.26	0.18	0.82	1.0	0.81	0.92	0.16	-0.78	0.81	0.57
Short Long Term Debt Total	0.8	0.73	-0.79	0.8	0.84	0.89	0.84		0.61	0.88	0.93	0.69	0.78	0.87	0.75	0.65	0.35	0.22	0.54	0.82	0.96	0.71	0.25	-0.53	0.79	0.8
Other Current Liab	0.79	0.7	-0.38	0.64	0.47	0.52	0.83	0.61		0.8	0.66	0.44	0.61	0.66	0.36	0.81	0.06	0.16	0.83	0.85	0.56	0.82	0.16	-0.51	0.59	0.41
Total Current Liabilities	0.95	0.86	-0.56	0.93	0.65	0.73	0.99	0.88	0.8		0.95	0.59	0.9	0.96	0.5	0.88	0.22	0.18	0.77	0.97	0.86	0.88	0.17	-0.77	0.86	0.63
Property Plant And Equipment Net	0.91	0.84	-0.6	0.94	0.67	0.76	0.93	0.93	0.66	0.95		0.61	0.87	0.97	0.53	0.78	0.39	0.24	0.66	0.91	0.92	0.8	0.23	-0.69	0.84	0.67
Accounts Payable	0.42	0.32	-0.87	0.52	0.86	0.85	0.51	0.69	0.44	0.59	0.61		0.39	0.56	0.82	0.23	-0.02	0.22	0.15	0.48	0.81	0.31	0.28	-0.15	0.81	0.69
Cash	0.89	0.83	-0.46	0.83	0.56	0.64	0.89	0.78	0.61	0.9	0.87	0.39		0.88	0.41	0.83	0.17	0.08	0.67	0.88	0.76	0.83	0.07	-0.94	0.73	0.62
Non Current Assets Total	0.94	0.88	-0.51	0.95	0.61	0.69	0.95	0.87	0.66	0.96	0.97	0.56	0.88		0.44	0.83	0.4	0.2	0.7	0.94	0.87	0.84	0.18	-0.74	0.83	0.58
Non Currrent Assets Other	0.32	0.21	-0.96	0.33	0.93	0.9	0.42	0.75	0.36	0.5	0.53	0.82	0.41	0.44		0.14	-0.13	0.3	0.03	0.41	0.81	0.24	0.4	-0.14	0.65	0.9
Cash And Short Term Investments	0.96	0.96	-0.22	0.79	0.37	0.46	0.92	0.65	0.81	0.88	0.78	0.23	0.83	0.83	0.14		0.37	-0.05	0.96	0.92	0.56	0.98	-0.09	-0.78	0.55	0.33
Net Receivables	0.41	0.54	0.0	0.31	0.08	0.15	0.26	0.35	0.06	0.22	0.39	-0.02	0.17	0.4	-0.13	0.37		-0.1	0.41	0.27	0.23	0.39	-0.13	-0.06	-0.02	-0.04
Common Stock Total Equity	0.06	-0.06	-0.13	0.23	0.06	0.09	0.18	0.22	0.16	0.18	0.24	0.22	0.08	0.2	0.3	-0.05	-0.1		-0.09	0.19	0.3	-0.02	0.99	-0.03	0.31	0.24
Short Term Investments	0.89	0.91	-0.11	0.69	0.26	0.35	0.82	0.54	0.83	0.77	0.66	0.15	0.67	0.7	0.03	0.96	0.41	-0.09		0.83	0.42	0.95	-0.14	-0.62	0.4	0.23
Non Current Liabilities Total	0.97	0.9	-0.45	0.9	0.56	0.64	1.0	0.82	0.85	0.97	0.91	0.48	0.88	0.94	0.41	0.92	0.27	0.19	0.83		0.79	0.93	0.16	-0.77	0.78	0.55
Property Plant And Equipment Gross	0.75	0.65	-0.84	0.8	0.88	0.92	0.81	0.96	0.56	0.86	0.92	0.81	0.76	0.87	0.81	0.56	0.23	0.3	0.42	0.79		0.63	0.34	-0.53	0.89	0.84
Total Current Assets	0.97	0.97	-0.32	0.79	0.46	0.55	0.92	0.71	0.82	0.88	0.8	0.31	0.83	0.84	0.24	0.98	0.39	-0.02	0.95	0.93	0.63		-0.05	-0.75	0.57	0.44
Common Stock	0.03	-0.1	-0.22	0.19	0.14	0.16	0.16	0.25	0.16	0.17	0.23	0.28	0.07	0.18	0.4	-0.09	-0.13	0.99	-0.14	0.16	0.34	-0.05		0.01	0.32	0.31
Net Debt	-0.78	-0.74	0.19	-0.72	-0.29	-0.37	-0.78	-0.53	-0.51	-0.77	-0.69	-0.15	-0.94	-0.74	-0.14	-0.78	-0.06	-0.03	-0.62	-0.77	-0.53	-0.75	0.01		-0.57	-0.4
Other Current Assets	0.7	0.56	-0.7	0.86	0.73	0.77	0.81	0.79	0.59	0.86	0.84	0.81	0.73	0.83	0.65	0.55	-0.02	0.31	0.4	0.78	0.89	0.57	0.32	-0.57		0.63
Property Plant Equipment	0.51	0.42	-0.86	0.46	0.86	0.87	0.57	0.8	0.41	0.63	0.67	0.69	0.62	0.58	0.9	0.33	-0.04	0.24	0.23	0.55	0.84	0.44	0.31	-0.4	0.63

Click cells to compare fundamentals

Sangamo Therapeutics Account Relationship Matchups

Sangamo Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	637.5M	938.6M	721.9M	562.5M	165.3M	218.1M
Total Stockholder Equity	432.7M	497.4M	375.3M	295.0M	82.9M	144.6M
Retained Earnings	(657.0M)	(778.0M)	(956.3M)	(1.1B)	(1.4B)	(1.3B)
Other Assets	10.6M	15.1M	16.8M	18.5M	1.0	0.95
Common Stock Shares Outstanding	112.1M	134.4M	144.6M	154.3M	174.4M	183.2M
Liabilities And Stockholders Equity	637.5M	938.6M	721.9M	562.5M	165.3M	218.1M
Other Stockholder Equity	1.1B	1.3B	1.3B	1.5B	1.5B	1.6B
Total Liab	204.8M	441.2M	346.6M	267.6M	82.4M	73.5M
Short Long Term Debt Total	44.4M	42.1M	48.1M	43.1M	38.1M	30.0M
Other Current Liab	21.3M	127.3M	28.4M	33.4M	27.9M	14.0M
Total Current Liabilities	69.9M	143.5M	127.9M	111.7M	47.7M	34.0M
Property Plant And Equipment Net	107.2M	112.4M	124.7M	125.5M	52.9M	29.2M
Accounts Payable	6.7M	12.6M	9.8M	22.4M	15.3M	16.0M
Cash	80.4M	131.3M	178.9M	100.4M	45.2M	45.0M
Non Current Assets Total	232.0M	278.9M	323.2M	262.2M	71.0M	68.1M
Non Currrent Assets Other	4.0M	7.9M	10.2M	12.3M	18.1M	19.0M
Cash And Short Term Investments	385.0M	692.0M	464.7M	277.6M	81.0M	77.0M
Net Receivables	37.6M	6.3M	6.4M	4.5M	1.3M	1.3M
Common Stock Total Equity	1.2M	1.4M	1.5M	1.7M	1.5M	1.4M
Short Term Investments	282.0M	510.1M	197.7M	177.2M	35.8M	34.0M
Non Current Liabilities Total	134.9M	297.6M	218.7M	155.8M	34.7M	57.7M
Property Plant And Equipment Gross	107.2M	112.4M	149.7M	162.1M	103.9M	109.1M
Total Current Assets	405.5M	659.7M	398.8M	300.3M	94.3M	175.7M
Accumulated Other Comprehensive Income	(2.4M)	5.4M	(4.0M)	(8.4M)	(4.6M)	(4.4M)
Common Stock	1.2M	1.4M	1.5M	1.7M	1.8M	1.7M
Net Debt	(36.0M)	(89.2M)	(130.8M)	(57.3M)	(7.1M)	(7.5M)
Other Current Assets	5.4M	24.0M	31.7M	36.4M	12M	12.6M
Property Plant Equipment	29.9M	41.3M	51.5M	63.5M	73.1M	76.7M
Current Deferred Revenue	38.7M	96.6M	85.7M	51.8M	59.5M	62.5M
Intangible Assets	53.2M	58.1M	53.8M	50.7M	58.3M	61.3M
Other Liab	93.7M	259.2M	174.6M	116.9M	134.4M	141.1M
Net Tangible Assets	340.1M	397.3M	281.9M	206.7M	237.7M	227.0M
Retained Earnings Total Equity	(657.0M)	(778.0M)	(956.3M)	(1.1B)	(1.0B)	(982.0M)
Capital Surpluse	1.1B	1.3B	1.3B	1.5B	1.7B	873.1M
Inventory	(22.5M)	(50.5M)	(88.2M)	1.0	0.9	0.95
Deferred Long Term Liab	6.6M	7.2M	6.6M	6.3M	7.2M	9.3M

Pair Trading with Sangamo Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangamo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Sangamo Stock

0.84	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.79	LLY	Eli Lilly	Pair Corr
0.76	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.72	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.67	VALN	Valneva SE ADR	Pair Corr

The ability to find closely correlated positions to Sangamo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangamo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangamo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangamo Therapeutics to buy it.

The correlation of Sangamo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangamo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangamo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Sangamo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:

How To Invest In Sangamo

Details

Is Sangamo Stock a good investment?

Details

What is Sangamo Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.

You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.24)

Revenue Per Share

0.066

Quarterly Revenue Growth

(0.95)

Return On Assets

(0.58)

Return On Equity

(1.94)

The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sangamo Payables Turnover vs Price To Sales Ratio Analysis

Payables Turnover vs Price To Sales Ratio

Payables Turnover vs Price To Sales Ratio Correlation Analysis

Correlation Coefficient

Payables Turnover

Price To Sales Ratio

Sangamo Therapeutics fundamental ratios Correlations

Sangamo Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sangamo Therapeutics fundamental ratios Accounts

Pair Trading with Sangamo Therapeutics

Moving against Sangamo Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Total Liab
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Total Current Liabilities	+ 0.99	Total Liab
Common Stock	+ 0.99	Common Stock Total Equity
Total Current Assets	+ 0.98	Cash And Short Term Investments
Total Stockholder Equity	+ 0.97	Total Assets

Common Stock Shares Outstanding	- 0.98	Retained Earnings
Non Currrent Assets Other	- 0.96	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Net Debt	- 0.94	Cash
Accounts Payable	- 0.87	Retained Earnings
Property Plant Equipment	- 0.86	Retained Earnings